Roche Considers Moving Two Drugs Into Phase III, Drops Early-Stage Alzheimer’s Compound In Strong 3rd Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche is moving into Phase III with a Lucentis successor, lampalizumab, in ophthalmology, but has dropped development of a Phase I BACE inhibitor for Alzheimer’s disease, the company announced during a third-quarter earnings update, which highlighted pipeline tweaks amid comparatively strong product sales.
You may also be interested in...
Biogen Hedges Its Bet On Alzheimer’s With Eisai Tie-Up
The big biotech and the Japanese pharma are teaming up to develop four Alzheimer’s treatments in a collaboration that will split development costs and share profits.
Emerging Markets Earnings Roundup: J&J, Abbott And Roche (Part 1)
Abbott moved to recover from recall and pricing issues for infant formula in China while Johnson & Johnson updated its device business and Roche reported strong growth in emerging markets.
Emerging Markets Earnings Roundup: J&J, Abbott And Roche (Part 1)
Abbott moved to recover from recall and pricing issues for infant formula in China while Johnson & Johnson updated its device business and Roche reported strong growth in emerging markets.